New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, ...

Several Wall Street firms raised price targets on Regeneron after its Q4 results. ・Q4 revenue and non-GAAP earnings both ...

Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 ...

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, ...

REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive ...

Regeneron Eylea challenges intensify as patent expires and biosimilars emerge. Learn how competition and FDA hurdles impact ...

Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch ...

European Commission grants marketing approval for Eylea 8 mg to treat macular edema following RVO, including branch, central and hemiretinal vein occlusion: Berlin Monday, January ...

Duravyu, combining vorolanib with a disintegrating matrix, improves vision and reduces supplemental treatments in diabetic macular edema patients. The phase 2 VERONA trial showed extended time to ...

On November 27, 2025, Celltrion announced that Health Canada approved EYDENZELT® (aflibercept-boav), a biosimilar referencing Regeneron’s EYLEA® (aflibercept), in both vial and pre-filled syringe form ...